A multi-stakeholder collaborative approach to awareness, education and support needed in the haemophilia gene therapy patient journey – a report on insights from a European patient advisory board

Gene therapy presents a potentially transformational approach to haemophilia management. The patient journey for gene therapy is unlike that for other haemophilia treatments, and its one-time, irreversible nature has led to broad agreement that informed shared decision-making is essential. Understan...

Full description

Saved in:
Bibliographic Details
Main Authors: O’Mahony Brian, Fletcher Simon, Baarslag Manuel, Khair Kate, Breederveld Daan, Jansen Nathalie, Pembroke Luke, Pinachyan Karen, Sivasubramaniyam Sujan
Format: Article
Language:English
Published: Sciendo 2024-04-01
Series:The Journal of Haemophilia Practice
Subjects:
Online Access:https://doi.org/10.2478/jhp-2024-0007
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832570318881816576
author O’Mahony Brian
Fletcher Simon
Baarslag Manuel
Khair Kate
Breederveld Daan
Jansen Nathalie
Pembroke Luke
Pinachyan Karen
Sivasubramaniyam Sujan
author_facet O’Mahony Brian
Fletcher Simon
Baarslag Manuel
Khair Kate
Breederveld Daan
Jansen Nathalie
Pembroke Luke
Pinachyan Karen
Sivasubramaniyam Sujan
author_sort O’Mahony Brian
collection DOAJ
description Gene therapy presents a potentially transformational approach to haemophilia management. The patient journey for gene therapy is unlike that for other haemophilia treatments, and its one-time, irreversible nature has led to broad agreement that informed shared decision-making is essential. Understanding the educational and support needs of people with haemophilia (PwH) who may consider or undergo gene therapy in the future is key to enabling this. A one-day patient advisory board was conducted with the aim of gaining insights on what education and support would enable PwH to have appropriate conversations with health care practitioners (HCPs) about gene therapy and participate in informed shared decision-making. The participants were 11 age-diverse men with severe haemophilia A or B, including six who had received gene therapy in phase 1-3 clinical trials. Two were members of a national patient organisation or a patient organisation leader. Participants agreed that informed shared decision-making was essential for gene therapy, but most felt the choice to have gene therapy would be limited by healthcare budgets and access arrangements. They identified key education needed by PwH to enable true informed decision-making, best delivered through a collaborative approach by patient organisations and HCPs. Eligibility criteria should be more widely shared within the community as part of general education around gene therapy. Gene therapy should be presented as one of a range of treatment options; understanding its risks, uncertainties and benefits is key to managing expectations and minimising treatment remorse. Awareness of how different factor levels impact bleeding tendency and frequency would be helpful, as success of gene therapy cannot be determined by factor activity alone. Other key educational needs included follow-up commitments, the role and potential side effects of corticosteroids or other immunosuppressants, impact on sense of identity, mental health, family planning, and managing bleeds after gene therapy. Teach-back could help ensure appropriate levels of understanding; psychological support could aid managing expectations. Peer-to-peer learning delivered across a variety of platforms, to share experiences of gene therapy and contextualise more ‘formal’ gene therapy education, was considered invaluable.
format Article
id doaj-art-b4272df270e046fc8cf8f06583c6b431
institution Kabale University
issn 2055-3390
language English
publishDate 2024-04-01
publisher Sciendo
record_format Article
series The Journal of Haemophilia Practice
spelling doaj-art-b4272df270e046fc8cf8f06583c6b4312025-02-02T15:48:30ZengSciendoThe Journal of Haemophilia Practice2055-33902024-04-01111475710.2478/jhp-2024-0007A multi-stakeholder collaborative approach to awareness, education and support needed in the haemophilia gene therapy patient journey – a report on insights from a European patient advisory boardO’Mahony Brian0Fletcher Simon1Baarslag Manuel2Khair Kate3Breederveld Daan4Jansen Nathalie5Pembroke Luke6Pinachyan Karen7Sivasubramaniyam Sujan8Irish Haemophilia Society, Dublin, IrelandHaemnet Ltd, London, UKRadboud UMC, Nijmegen, The NetherlandsHaemnet Ltd, London, UKBrendaan Consultancy, Amsterdam, The NetherlandsCSL Behring, Hattersheim am Main, GermanyHaemnet Ltd, London, UKCSL Behring, Hattersheim am Main, GermanyCSL Behring, Hattersheim am Main, GermanyGene therapy presents a potentially transformational approach to haemophilia management. The patient journey for gene therapy is unlike that for other haemophilia treatments, and its one-time, irreversible nature has led to broad agreement that informed shared decision-making is essential. Understanding the educational and support needs of people with haemophilia (PwH) who may consider or undergo gene therapy in the future is key to enabling this. A one-day patient advisory board was conducted with the aim of gaining insights on what education and support would enable PwH to have appropriate conversations with health care practitioners (HCPs) about gene therapy and participate in informed shared decision-making. The participants were 11 age-diverse men with severe haemophilia A or B, including six who had received gene therapy in phase 1-3 clinical trials. Two were members of a national patient organisation or a patient organisation leader. Participants agreed that informed shared decision-making was essential for gene therapy, but most felt the choice to have gene therapy would be limited by healthcare budgets and access arrangements. They identified key education needed by PwH to enable true informed decision-making, best delivered through a collaborative approach by patient organisations and HCPs. Eligibility criteria should be more widely shared within the community as part of general education around gene therapy. Gene therapy should be presented as one of a range of treatment options; understanding its risks, uncertainties and benefits is key to managing expectations and minimising treatment remorse. Awareness of how different factor levels impact bleeding tendency and frequency would be helpful, as success of gene therapy cannot be determined by factor activity alone. Other key educational needs included follow-up commitments, the role and potential side effects of corticosteroids or other immunosuppressants, impact on sense of identity, mental health, family planning, and managing bleeds after gene therapy. Teach-back could help ensure appropriate levels of understanding; psychological support could aid managing expectations. Peer-to-peer learning delivered across a variety of platforms, to share experiences of gene therapy and contextualise more ‘formal’ gene therapy education, was considered invaluable.https://doi.org/10.2478/jhp-2024-0007haemophiliagene therapypatient educationshared decision-making
spellingShingle O’Mahony Brian
Fletcher Simon
Baarslag Manuel
Khair Kate
Breederveld Daan
Jansen Nathalie
Pembroke Luke
Pinachyan Karen
Sivasubramaniyam Sujan
A multi-stakeholder collaborative approach to awareness, education and support needed in the haemophilia gene therapy patient journey – a report on insights from a European patient advisory board
The Journal of Haemophilia Practice
haemophilia
gene therapy
patient education
shared decision-making
title A multi-stakeholder collaborative approach to awareness, education and support needed in the haemophilia gene therapy patient journey – a report on insights from a European patient advisory board
title_full A multi-stakeholder collaborative approach to awareness, education and support needed in the haemophilia gene therapy patient journey – a report on insights from a European patient advisory board
title_fullStr A multi-stakeholder collaborative approach to awareness, education and support needed in the haemophilia gene therapy patient journey – a report on insights from a European patient advisory board
title_full_unstemmed A multi-stakeholder collaborative approach to awareness, education and support needed in the haemophilia gene therapy patient journey – a report on insights from a European patient advisory board
title_short A multi-stakeholder collaborative approach to awareness, education and support needed in the haemophilia gene therapy patient journey – a report on insights from a European patient advisory board
title_sort multi stakeholder collaborative approach to awareness education and support needed in the haemophilia gene therapy patient journey a report on insights from a european patient advisory board
topic haemophilia
gene therapy
patient education
shared decision-making
url https://doi.org/10.2478/jhp-2024-0007
work_keys_str_mv AT omahonybrian amultistakeholdercollaborativeapproachtoawarenesseducationandsupportneededinthehaemophiliagenetherapypatientjourneyareportoninsightsfromaeuropeanpatientadvisoryboard
AT fletchersimon amultistakeholdercollaborativeapproachtoawarenesseducationandsupportneededinthehaemophiliagenetherapypatientjourneyareportoninsightsfromaeuropeanpatientadvisoryboard
AT baarslagmanuel amultistakeholdercollaborativeapproachtoawarenesseducationandsupportneededinthehaemophiliagenetherapypatientjourneyareportoninsightsfromaeuropeanpatientadvisoryboard
AT khairkate amultistakeholdercollaborativeapproachtoawarenesseducationandsupportneededinthehaemophiliagenetherapypatientjourneyareportoninsightsfromaeuropeanpatientadvisoryboard
AT breedervelddaan amultistakeholdercollaborativeapproachtoawarenesseducationandsupportneededinthehaemophiliagenetherapypatientjourneyareportoninsightsfromaeuropeanpatientadvisoryboard
AT jansennathalie amultistakeholdercollaborativeapproachtoawarenesseducationandsupportneededinthehaemophiliagenetherapypatientjourneyareportoninsightsfromaeuropeanpatientadvisoryboard
AT pembrokeluke amultistakeholdercollaborativeapproachtoawarenesseducationandsupportneededinthehaemophiliagenetherapypatientjourneyareportoninsightsfromaeuropeanpatientadvisoryboard
AT pinachyankaren amultistakeholdercollaborativeapproachtoawarenesseducationandsupportneededinthehaemophiliagenetherapypatientjourneyareportoninsightsfromaeuropeanpatientadvisoryboard
AT sivasubramaniyamsujan amultistakeholdercollaborativeapproachtoawarenesseducationandsupportneededinthehaemophiliagenetherapypatientjourneyareportoninsightsfromaeuropeanpatientadvisoryboard
AT omahonybrian multistakeholdercollaborativeapproachtoawarenesseducationandsupportneededinthehaemophiliagenetherapypatientjourneyareportoninsightsfromaeuropeanpatientadvisoryboard
AT fletchersimon multistakeholdercollaborativeapproachtoawarenesseducationandsupportneededinthehaemophiliagenetherapypatientjourneyareportoninsightsfromaeuropeanpatientadvisoryboard
AT baarslagmanuel multistakeholdercollaborativeapproachtoawarenesseducationandsupportneededinthehaemophiliagenetherapypatientjourneyareportoninsightsfromaeuropeanpatientadvisoryboard
AT khairkate multistakeholdercollaborativeapproachtoawarenesseducationandsupportneededinthehaemophiliagenetherapypatientjourneyareportoninsightsfromaeuropeanpatientadvisoryboard
AT breedervelddaan multistakeholdercollaborativeapproachtoawarenesseducationandsupportneededinthehaemophiliagenetherapypatientjourneyareportoninsightsfromaeuropeanpatientadvisoryboard
AT jansennathalie multistakeholdercollaborativeapproachtoawarenesseducationandsupportneededinthehaemophiliagenetherapypatientjourneyareportoninsightsfromaeuropeanpatientadvisoryboard
AT pembrokeluke multistakeholdercollaborativeapproachtoawarenesseducationandsupportneededinthehaemophiliagenetherapypatientjourneyareportoninsightsfromaeuropeanpatientadvisoryboard
AT pinachyankaren multistakeholdercollaborativeapproachtoawarenesseducationandsupportneededinthehaemophiliagenetherapypatientjourneyareportoninsightsfromaeuropeanpatientadvisoryboard
AT sivasubramaniyamsujan multistakeholdercollaborativeapproachtoawarenesseducationandsupportneededinthehaemophiliagenetherapypatientjourneyareportoninsightsfromaeuropeanpatientadvisoryboard